# Incretin Atlas > A living, openly licensed database of trial results for GLP-1 receptor agonists, dual and triple agonists and amylin analogues, with a primary source and a verbatim quote behind every number. By Medical Adviser's Group. Data cut 12 November 2026. Data on Zenodo: https://doi.org/10.5281/zenodo.23473913 (CC BY 4.0). - [Incretin Atlas, main page with interactive maps](https://docs.mdwrt.app/infographics/incretin-atlas/): effect vs tolerability map, arms, outcome trials, timeline, pipeline, indirect comparisons - [About: authors, method, corrections, how to cite](https://docs.mdwrt.app/infographics/incretin-atlas/about/) - [Full plain-text export of all records](https://docs.mdwrt.app/llms-full.txt) ## Molecules - [Semaglutide](https://docs.mdwrt.app/infographics/incretin-atlas/semaglutide/): GLP-1; s.c. / oral; Novo Nordisk; Approved: obesity, T2D, MACE reduction, CKD in T2D (Ozempic), MASH (Wegovy US 2025; Kayshild EU 2026); oral Wegovy tablets - [Tirzepatide](https://docs.mdwrt.app/infographics/incretin-atlas/tirzepatide/): GIP/GLP-1; s.c.; Eli Lilly; Approved: obesity, T2D, obstructive sleep apnoea (FDA); MACE reduction added to the Mounjaro US label (2026) - [Liraglutide](https://docs.mdwrt.app/infographics/incretin-atlas/liraglutide/): GLP-1; s.c. daily; Novo Nordisk / generics; Approved for obesity (2014); generics available - [Orforglipron](https://docs.mdwrt.app/infographics/incretin-atlas/orforglipron/): GLP-1 (small molecule); oral; Eli Lilly; Approved in the US for obesity (Foundayo, 2026); T2D phase 3 positive (ACHIEVE) - [CagriSema](https://docs.mdwrt.app/infographics/incretin-atlas/cagrisema/): GLP-1 + amylin; s.c.; Novo Nordisk; Phase 3 (REDEFINE); filing 2026 - [Retatrutide](https://docs.mdwrt.app/infographics/incretin-atlas/retatrutide/): GIP/GLP-1/GCG; s.c.; Eli Lilly; Phase 3 positive: TRIUMPH-1 (NEJM 2026), TRIUMPH-2/-3 and TRIUMPH-4 toplines; TRANSCEND-T2D-1 at EASD 2026 - [Survodutide](https://docs.mdwrt.app/infographics/incretin-atlas/survodutide/): GLP-1/GCG; s.c.; Boehringer Ingelheim / Zealand; Phase 3 positive in obesity (SYNCHRONIZE-1, NEJM 2026) and T2D (SYNCHRONIZE-2, NEJM 2026); SYNCHRONIZE-CVOT showed CV safety (non-inferior to placebo, Lancet Nov 2026) - [Mazdutide](https://docs.mdwrt.app/infographics/incretin-atlas/mazdutide/): GLP-1/GCG; s.c.; Innovent (Lilly licence); Approved in China: obesity (June 2025) and T2D (September 2025); 9 mg supplementary NDA accepted (Nov 2025); GLORY-2 published (JAMA 2026) - [MariTide](https://docs.mdwrt.app/infographics/incretin-atlas/maritide/): GLP-1 + GIPR antagonist (antibody); s.c. monthly; Amgen; Phase 3 (MARITIME) - [Amycretin](https://docs.mdwrt.app/infographics/incretin-atlas/amycretin/): GLP-1 + amylin (unimolecular); s.c. / oral; Novo Nordisk; Phase 3 (AMAZE) started - [Eloralintide](https://docs.mdwrt.app/infographics/incretin-atlas/eloralintide/): Amylin; s.c.; Eli Lilly; Phase 3 ENLIGHTEN programme recruiting since Dec 2025 (obesity, T2D, sleep apnoea, knee osteoarthritis, maintenance after incretin therapy); phase 2 complete - [Petrelintide](https://docs.mdwrt.app/infographics/incretin-atlas/petrelintide/): Amylin; s.c.; Zealand / Roche; Phase 3 ZUPREME programme (ZUPREME-3, -4, -5) initiated with Roche; phase 2 ZUPREME-1 published (Lancet Diabetes Endocrinol 2026), ZUPREME-2 topline in T2D (Oct 2026) - [CT-388](https://docs.mdwrt.app/infographics/incretin-atlas/ct-388/): GIP/GLP-1; s.c.; Roche; Phase 3 (Enith1, Enith2 and a third trial) recruiting since Mar 2026; phase 2 (48 weeks) presented at EASD 2026 - [Pemvidutide](https://docs.mdwrt.app/infographics/incretin-atlas/pemvidutide/): GLP-1/GCG; s.c.; Altimmune; Phase 3 PERFORMA in MASH recruiting since Jul 2026; phase 2 MOMENTUM (obesity) and IMPACT (MASH) complete - [Ecnoglutide](https://docs.mdwrt.app/infographics/incretin-atlas/ecnoglutide/): GLP-1 (biased agonist); s.c.; Sciwind; Approved in China: T2D (January 2026) and weight management (March 2026); SLIMMER published (Lancet Diabetes Endocrinol 2025) - [Ribupatide (HRS9531)](https://docs.mdwrt.app/infographics/incretin-atlas/ribupatide/): GIP/GLP-1; s.c.; Hengrui / Kailera; Phase 3 positive in China (GEMINI-1: −17.7 % TP / −19.2 % at 48 weeks); NDA accepted in China (Sep 2025); global phase 3 KaiNETIC enrolled (Kailera) - [UBT251](https://docs.mdwrt.app/infographics/incretin-atlas/ubt251/): GIP/GLP-1/GCG; s.c.; United Laboratories (Novo Nordisk licence); Phase 3 in China: UNIGUIDE-1 (T2D) recruiting since Sep 2026; obesity and sleep apnoea trials registered; phase 2 (T2D) at EASD 2026 - [Efinopegdutide](https://docs.mdwrt.app/infographics/incretin-atlas/efinopegdutide/): GLP-1/GCG; s.c.; MSD (Hanmi); Phase 2b MASH - [RGT-075](https://docs.mdwrt.app/infographics/incretin-atlas/rgt-075/): GLP-1 (small molecule); oral; Regor; Phase 2b (36 weeks) presented at EASD 2026 - [HRS-7535](https://docs.mdwrt.app/infographics/incretin-atlas/hrs-7535/): GLP-1 (small molecule); oral; Hengrui; Phase 3 positive: OUTSTAND-1/-2 (T2D), HARBOR-1 (obesity); NDAs accepted in China for T2D and weight management (Sep 2026) - [Dulaglutide](https://docs.mdwrt.app/infographics/incretin-atlas/dulaglutide/): GLP-1; s.c.; Eli Lilly; Approved (T2D); not developed for obesity - [Efpeglenatide](https://docs.mdwrt.app/infographics/incretin-atlas/efpeglenatide/): GLP-1; s.c.; Hanmi; Positive CVOT (AMPLITUDE-O); development paused - [Albiglutide](https://docs.mdwrt.app/infographics/incretin-atlas/albiglutide/): GLP-1; s.c.; GSK; Withdrawn from market (2018) despite positive CVOT - [Exenatide](https://docs.mdwrt.app/infographics/incretin-atlas/exenatide/): GLP-1; s.c.; AstraZeneca; Approved (T2D) - [Lixisenatide](https://docs.mdwrt.app/infographics/incretin-atlas/lixisenatide/): GLP-1; s.c.; Sanofi; Approved (T2D); neutral CVOT - [VK2735](https://docs.mdwrt.app/infographics/incretin-atlas/vk2735/): GIP/GLP-1; s.c. / oral; Viking Therapeutics; Phase 3: s.c. VANQUISH-1/-2 (since 2025); oral SUNRISE-1/-2 started Oct 2026 (obesity with and without T2D); VENTURE s.c. phase 2 published (Obesity 2026) - [Berobenatide (MET-097i)](https://docs.mdwrt.app/infographics/incretin-atlas/berobenatide/): GLP-1 (ultra-long-acting, monthly); s.c. monthly; Pfizer (Metsera); Phase 3 started 2026 (monthly dosing); phase 2b VESPER reported 2025 - [CT-996](https://docs.mdwrt.app/infographics/incretin-atlas/ct-996/): GLP-1 (small molecule); oral; Roche; Phase 2 - [Aleniglipron](https://docs.mdwrt.app/infographics/incretin-atlas/aleniglipron/): GLP-1 (small molecule); oral; Structure Therapeutics; Two pivotal phase 3 trials (obesity; obesity with or without T2D) recruiting since Jul 2026; phase 2b ACCESS reported 2025 - [Dapiglutide](https://docs.mdwrt.app/infographics/incretin-atlas/dapiglutide/): GLP-1/GLP-2; s.c.; Zealand Pharma; Phase 2 - [Danuglipron](https://docs.mdwrt.app/infographics/incretin-atlas/danuglipron/): GLP-1 (small molecule); oral; Pfizer; Discontinued (2025, liver safety signal) - [BGM0504](https://docs.mdwrt.app/infographics/incretin-atlas/bgm0504/): GIP/GLP-1; s.c.; BrightGene; Phase 3 positive in China (52 weeks, up to −19.2 %); NDA accepted (June 2026) - [HDM1702](https://docs.mdwrt.app/infographics/incretin-atlas/hdm1702/): GLP-1; s.c.; Huadong Medicine; Semaglutide follow-on: phase 3 equivalence to Wegovy; NDAs accepted in China (T2D Mar 2025; weight Apr 2026) - [HDM1005](https://docs.mdwrt.app/infographics/incretin-atlas/hdm1005/): GIP/GLP-1; s.c.; Huadong Medicine; Phase 3 in China (obesity; T2D; head-to-head vs mazdutide in T2D) since Oct 2025; phase 2 T2D (20 wk) at EASD 2026: HbA1c up to −2.57 % - [RAY1225](https://docs.mdwrt.app/infographics/incretin-atlas/ray1225/): GIP/GLP-1; s.c. every 2 weeks; Raynovent; Phase 3 REBUILDING-2 positive (9 mg every 2 weeks: −22.2 % at 52 weeks, topline Oct 2026); licensed to Qilu - [TG103](https://docs.mdwrt.app/infographics/incretin-atlas/tg103/): GLP-1; s.c.; CSPC; Efmedaglutide alfa. Phase 3 T2D non-inferior to dulaglutide; obesity NDA accepted in China (Oct 2025) - [Bofanglutide (GZR18)](https://docs.mdwrt.app/infographics/incretin-atlas/bofanglutide/): GLP-1; s.c. every 2 weeks; Gan & Lee; Phase 3 GRADUAL-1 positive (48 mg every 2 weeks: −18.5 % at 52 weeks); US phase 2; once-monthly GRADUAL-3 started - [HRS-4729](https://docs.mdwrt.app/infographics/incretin-atlas/hrs-4729/): GIP/GLP-1/GCG; s.c.; Hengrui; Phase 2 master protocol in MASH recruiting since Aug 2026; phase 1 at EASD 2026 - [DD1013](https://docs.mdwrt.app/infographics/incretin-atlas/dd1013/): GLP-1 + GIP + amylin (triple); s.c.; Huadong Medicine; Preclinical (EASD 2026) - [ASC35 / ASC36](https://docs.mdwrt.app/infographics/incretin-atlas/asc35-asc36/): GIP/GLP-1 + amylin (monthly co-formulation); s.c. monthly; Ascletis; Phase 1 single and multiple ascending dose study recruiting since Aug 2026; preclinical data at EASD 2026 - [HS-20094](https://docs.mdwrt.app/infographics/incretin-atlas/hs-20094/): GIP/GLP-1; s.c.; Hansoh; Olatorepatide. Phase 3 LIGHTEN positive in China (−18.7 % at 48 weeks, EASD 2026); NDA accepted (June 2026); Regeneron licence ex-China - [ASC30](https://docs.mdwrt.app/infographics/incretin-atlas/asc30/): GLP-1 (small molecule); oral / s.c.; Ascletis; Oral phase 2 (13 weeks: placebo-adjusted −7.7 %); global phase 3 AURORA started (Aug 2026) - [HDM1002](https://docs.mdwrt.app/infographics/incretin-atlas/hdm1002/): GLP-1 (small molecule); oral; Huadong Medicine; Phase 3 HDM1002-301 positive (oral; up to −12.2 % efficacy estimand at 52 weeks); pre-NDA - [AZD5004 (ECC5004)](https://docs.mdwrt.app/infographics/incretin-atlas/azd5004/): GLP-1 (small molecule); oral; AstraZeneca (Eccogene); Elecoglipron. Phase 2b VISTA (obesity) and SOLSTICE (T2D) positive; phase 3 started (June 2026) - [DR10624](https://docs.mdwrt.app/infographics/incretin-atlas/dr10624/): GLP-1/GCG/FGF21; s.c.; Doer Biologics; Phase 3 in severe hypertriglyceridaemia; obesity/MASH in development - [Efsubaglutide alfa (supaglutide)](https://docs.mdwrt.app/infographics/incretin-atlas/efsubaglutide-alfa/): GLP-1; s.c. weekly; Yinnuo (Innogen); Approved in China for T2D (January 2025); obesity phase 2b ENLIGHT positive; obesity phase 3 topline expected end-2026 - [PB-119](https://docs.mdwrt.app/infographics/incretin-atlas/pb-119/): GLP-1; s.c. weekly; PegBio; Approved in China for T2D (November 2025) - [PEG-loxenatide](https://docs.mdwrt.app/infographics/incretin-atlas/peg-loxenatide/): GLP-1; s.c. weekly; Hansoh; Approved in China for T2D (May 2019, Fulaimei) - [Beinaglutide](https://docs.mdwrt.app/infographics/incretin-atlas/beinaglutide/): GLP-1; s.c. daily; Benemae; Approved in China: T2D (2016), weight management (2023) - [HEC88473](https://docs.mdwrt.app/infographics/incretin-atlas/hec88473/): GLP-1/FGF21; s.c.; HEC; Phase 2 - [Zovaglutide](https://docs.mdwrt.app/infographics/incretin-atlas/zovaglutide/): GLP-1 (ultra-long-acting, monthly); s.c.; QL Biopharm; Phase 3 in obesity (HORIZON-1, China, started Jan 2026) - [Noiiglutide](https://docs.mdwrt.app/infographics/incretin-atlas/noiiglutide/): GLP-1; s.c.; Hengrui; Phase 3 in T2D (China) completed; results not yet public - [Lenbelintide](https://docs.mdwrt.app/infographics/incretin-atlas/lenbelintide/): Amylin; s.c.; AstraZeneca; Phase 3 recruiting (adjunct to incretin-based therapy, 68 weeks) - [Efocipegtrutide](https://docs.mdwrt.app/infographics/incretin-atlas/efocipegtrutide/): GIP/GLP-1/GCG; s.c.; Hanmi; Phase 2 in biopsy-confirmed MASH - [Macupatide](https://docs.mdwrt.app/infographics/incretin-atlas/macupatide/): GIP; s.c.; Eli Lilly; Phase 2 (alone and with eloralintide) - [Cotadutide](https://docs.mdwrt.app/infographics/incretin-atlas/cotadutide/): GLP-1/GCG; s.c.; AstraZeneca; Phase 2 (MASH, CKD with T2D) completed; no phase 3 registered - [EloraTZP](https://docs.mdwrt.app/infographics/incretin-atlas/eloratzp/): GIP/GLP-1 + amylin; s.c.; Eli Lilly; Phase 2b in obesity with T2D positive (Sep 2026: up to −23.3 % vs −14.8 % with tirzepatide 15 mg); phase 3 AMPLIFY-1 and AMPLIFY-2 registered (100 weeks, start Q4 2026) ## Trials - [STEP 1](https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-1/): Semaglutide - [STEP UP](https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-up/): Semaglutide - [STEP 2](https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-2/): Semaglutide - [OASIS 4](https://docs.mdwrt.app/infographics/incretin-atlas/trials/oasis-4/): Semaglutide - [SURMOUNT-1](https://docs.mdwrt.app/infographics/incretin-atlas/trials/surmount-1/): Tirzepatide - [SURMOUNT-2](https://docs.mdwrt.app/infographics/incretin-atlas/trials/surmount-2/): Tirzepatide - [SURMOUNT-5 (head-to-head)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/surmount-5/): Tirzepatide - [Retatrutide phase 2 (obesity)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/retatrutide-phase-2-obesity/): Retatrutide - [Retatrutide phase 2 (T2D)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/retatrutide-phase-2-t2d/): Retatrutide - [TRANSCEND-T2D-1 (T2D monotherapy)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/transcend-t2d-1/): Retatrutide - [REDEFINE 1](https://docs.mdwrt.app/infographics/incretin-atlas/trials/redefine-1/): CagriSema - [REDEFINE 2](https://docs.mdwrt.app/infographics/incretin-atlas/trials/redefine-2/): CagriSema - [REIMAGINE 1 (early T2D)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/reimagine-1/): CagriSema - [Survodutide phase 2 (obesity)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/survodutide-phase-2/): Survodutide - [Amycretin s.c. phase 1b/2a](https://docs.mdwrt.app/infographics/incretin-atlas/trials/amycretin-s-c-phase-1b-2a/): Amycretin - [Amycretin oral phase 1](https://docs.mdwrt.app/infographics/incretin-atlas/trials/amycretin-oral-phase-1/): Amycretin - [ATTAIN-1](https://docs.mdwrt.app/infographics/incretin-atlas/trials/attain-1/): Orforglipron - [ATTAIN-2 (obesity + T2D)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/attain-2/): Orforglipron - [ACHIEVE-1](https://docs.mdwrt.app/infographics/incretin-atlas/trials/achieve-1/): Orforglipron - [MOMENTUM](https://docs.mdwrt.app/infographics/incretin-atlas/trials/momentum/): Pemvidutide - [CT-388 phase 2](https://docs.mdwrt.app/infographics/incretin-atlas/trials/ct-388-phase-2/): CT-388 - [RGT-075 phase 2b](https://docs.mdwrt.app/infographics/incretin-atlas/trials/rgt-075-phase-2b/): RGT-075 - [Ribupatide phase 2 (obesity + PMOS)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/ribupatide-phase-2/): Ribupatide (HRS9531) - [BGM0504 phase 3 (obesity)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/bgm0504-phase-3/): BGM0504 - [HDM1702 vs Wegovy (bioequivalence)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/hdm1702-vs-wegovy/): HDM1702 - [Shining-1 (T2D)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/shining-1/): RAY1225 - [HDM1005 phase 2 (T2D)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/hdm1005-phase-2/): HDM1005 - [OUTSTAND-1 (early T2D, monotherapy)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/outstand-1/): HRS-7535 - [TG103 phase 3 vs dulaglutide (T2D)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/tg103-phase-3-vs-dulaglutide/): TG103 - [TRIUMPH-1](https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-1/): Retatrutide - [SYNCHRONIZE-1](https://docs.mdwrt.app/infographics/incretin-atlas/trials/synchronize-1/): Survodutide - [REDEFINE 5 (vs semaglutide 2.4 mg)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/redefine-5/): CagriSema - [VENTURE (phase 2, s.c.)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/venture/): VK2735 - [Zenagamtide s.c. phase 2 (T2D)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/zenagamtide-s-c-phase-2/): Amycretin - [VENTURE-Oral (phase 2)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/venture-oral/): VK2735 - [TRIUMPH-4 (obesity + knee osteoarthritis)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-4/): Retatrutide - [UBT251 phase 2 (obesity)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/ubt251-phase-2-obesity/): UBT251 - [UBT251 phase 2 (T2D)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/ubt251-phase-2-t2d/): UBT251 - [US phase 2 (NCT06124807)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/us-phase-2-nct06124807/): Mazdutide - [DREAMS-1](https://docs.mdwrt.app/infographics/incretin-atlas/trials/dreams-1/): Mazdutide - [DREAMS-3](https://docs.mdwrt.app/infographics/incretin-atlas/trials/dreams-3/): Mazdutide - [SLIMMER](https://docs.mdwrt.app/infographics/incretin-atlas/trials/slimmer/): Ecnoglutide - [SLIMMER-UP-SWITCH (interim)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/slimmer-up-switch/): Ecnoglutide - [EECOH-1](https://docs.mdwrt.app/infographics/incretin-atlas/trials/eecoh-1/): Ecnoglutide - [EECOH-2](https://docs.mdwrt.app/infographics/incretin-atlas/trials/eecoh-2/): Ecnoglutide - [LIGHTEN (HS-20094-301)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/lighten/): HS-20094 - [PEX168 monotherapy phase 3a](https://docs.mdwrt.app/infographics/incretin-atlas/trials/pex168-monotherapy-phase-3a/): PEG-loxenatide - [PEX168 add-on to metformin phase 3b](https://docs.mdwrt.app/infographics/incretin-atlas/trials/pex168-add-on-to-metformin-phase-3b/): PEG-loxenatide - [HRS9531-301 (GEMINI-1, NCT06396429)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs9531-301/): Ribupatide (HRS9531) - [HRS9531-203 (NCT06054698)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs9531-203/): Ribupatide (HRS9531) - [HRS9531-201 (NCT05881837)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs9531-201/): Ribupatide (HRS9531) - [HRS9531-T-201 oral ribupatide (NCT06841445)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs9531-t-201-oral-ribupatide/): Ribupatide (HRS9531) - [Ribupatide in obesity + PMOS (NCT06595797)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/ribupatide-in-obesity-pmos/): Ribupatide (HRS9531) - [Ribupatide T2D phase 3 after metformin +/- SGLT2i (NCT06649344)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/ribupatide-t2d-phase-3-after-metformin-sglt2i/): Ribupatide (HRS9531) - [OUTSTAND-2 (HRS-7535-302, NCT06589765)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/outstand-2/): HRS-7535 - [HARBOR-1 (HRS-7535-303, NCT06904105)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/harbor-1/): HRS-7535 - [HRS-4729 phase 1 SAD/MAD, MAD part (NCT06762600)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs-4729-phase-1-sad-mad-mad-part/): HRS-4729 - [UBT251 phase 2 obesity China (NCT07177469)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/ubt251-phase-2-obesity-china/): UBT251 - [UBT251 phase 2 T2D China (NCT07163624)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/ubt251-phase-2-t2d-china/): UBT251 - [REBUILDING-2 (RAY1225, NCT06893016)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/rebuilding-2/): RAY1225 - [REBUILDING-1 (RAY1225, NCT06254261)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/rebuilding-1/): RAY1225 - [Phase 2b CTR20231695](https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-2b-ctr20231695/): Bofanglutide (GZR18) - [Phase 2b CTR20232069 (vs semaglutide)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-2b-ctr20232069/): Bofanglutide (GZR18) - [GRADUAL-1 (NCT06728124)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/gradual-1/): Bofanglutide (GZR18) - [US Phase 2 (NCT06737042)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/us-phase-2-nct06737042/): Bofanglutide (GZR18) - [Phase III TG103 + metformin vs dulaglutide (EASD 2026)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-iii-tg103-metformin-vs-dulaglutide/): TG103 - [HDM1002-301](https://docs.mdwrt.app/infographics/incretin-atlas/trials/hdm1002-301/): HDM1002 - [China Phase II (obesity, non-diabetic)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/china-phase-ii/): HDM1005 - [VISTA (NCT06579092)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/vista/): AZD5004 (ECC5004) - [SOLSTICE (NCT06579105)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/solstice/): AZD5004 (ECC5004) - [ENLIGHT Phase IIb (NCT06921486)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/enlight-phase-iib/): Efsubaglutide alfa (supaglutide) - [SUPER 2 (NCT04998032), phase 3 stage](https://docs.mdwrt.app/infographics/incretin-atlas/trials/super-2-phase-3-stage/): Efsubaglutide alfa (supaglutide) - [Phase 3 monotherapy (NCT04504370)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-3-monotherapy/): PB-119 - [Phase 3 add-on to metformin (Lancet RH-WP 2024;51:101197)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-3-add-on-to-metformin/): PB-119 - [Phase 3 weight management (ChiCTR1900023428)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-3-weight-management/): Beinaglutide - [TRIUMPH-2 (obesity + T2D)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-2/): Retatrutide - [SYNCHRONIZE-2 (obesity + T2D)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/synchronize-2/): Survodutide - [ZUPREME-1](https://docs.mdwrt.app/infographics/incretin-atlas/trials/zupreme-1/): Petrelintide - [ZUPREME-2 (obesity + T2D)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/zupreme-2/): Petrelintide - [REIMAGINE 5 (vs tirzepatide 5 mg)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/reimagine-5/): CagriSema - [REDEFINE 9](https://docs.mdwrt.app/infographics/incretin-atlas/trials/redefine-9/): CagriSema - [EloraTZP phase 2b (obesity + T2D)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/eloratzp-phase-2b/): EloraTZP, Eloralintide, Tirzepatide - [CT-388-104 (T2D)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/ct-388-104/): CT-388 - [BGM0504 phase 2 (China, obesity)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/bgm0504-phase-2/): BGM0504 - [ACHIEVE-2 (vs dapagliflozin)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/achieve-2/): Orforglipron - [GLORY-1](https://docs.mdwrt.app/infographics/incretin-atlas/trials/glory-1/): Mazdutide - [GLORY-2](https://docs.mdwrt.app/infographics/incretin-atlas/trials/glory-2/): Mazdutide - [DREAMS-2](https://docs.mdwrt.app/infographics/incretin-atlas/trials/dreams-2/): Mazdutide - [ACCESS (phase 2b)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/access/): Aleniglipron - [HRS-7535 phase 2 (add-on to metformin + SGLT2i)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs-7535-phase-2/): HRS-7535 - [MariTide phase 2 (obesity cohort)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/maritide-phase-2/): MariTide - [TRANSCEND-T2D-2 (vs semaglutide 2 mg)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/transcend-t2d-2/): Retatrutide - [ATTAIN-J (Japan)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/attain-j/): Orforglipron - [SYNCHRONIZE-CVOT](https://docs.mdwrt.app/infographics/incretin-atlas/trials/synchronize-cvot/): Survodutide - [SELECT](https://docs.mdwrt.app/infographics/incretin-atlas/trials/select/): Semaglutide - [FLOW](https://docs.mdwrt.app/infographics/incretin-atlas/trials/flow/): Semaglutide - [SOUL](https://docs.mdwrt.app/infographics/incretin-atlas/trials/soul/): Semaglutide - [SUSTAIN-6](https://docs.mdwrt.app/infographics/incretin-atlas/trials/sustain-6/): Semaglutide - [PIONEER 6](https://docs.mdwrt.app/infographics/incretin-atlas/trials/pioneer-6/): Semaglutide - [LEADER](https://docs.mdwrt.app/infographics/incretin-atlas/trials/leader/): Liraglutide - [SURPASS-CVOT](https://docs.mdwrt.app/infographics/incretin-atlas/trials/surpass-cvot/): Tirzepatide - [SUMMIT](https://docs.mdwrt.app/infographics/incretin-atlas/trials/summit/): Tirzepatide - [REWIND](https://docs.mdwrt.app/infographics/incretin-atlas/trials/rewind/): Dulaglutide - [AMPLITUDE-O](https://docs.mdwrt.app/infographics/incretin-atlas/trials/amplitude-o/): Efpeglenatide - [Harmony Outcomes](https://docs.mdwrt.app/infographics/incretin-atlas/trials/harmony-outcomes/): Albiglutide - [EXSCEL](https://docs.mdwrt.app/infographics/incretin-atlas/trials/exscel/): Exenatide - [ELIXA](https://docs.mdwrt.app/infographics/incretin-atlas/trials/elixa/): Lixisenatide - [ACHIEVE-4](https://docs.mdwrt.app/infographics/incretin-atlas/trials/achieve-4/): Orforglipron - [STEP-HFpEF](https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-hfpef/): Semaglutide - [STEP-HFpEF DM](https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-hfpef-dm/): Semaglutide - [SURMOUNT-OSA](https://docs.mdwrt.app/infographics/incretin-atlas/trials/surmount-osa/): Tirzepatide - [STEP 9](https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-9/): Semaglutide - [ESSENCE (part 1)](https://docs.mdwrt.app/infographics/incretin-atlas/trials/essence/): Semaglutide - [SYNERGY-NASH](https://docs.mdwrt.app/infographics/incretin-atlas/trials/synergy-nash/): Tirzepatide - [Survodutide phase 2 MASH](https://docs.mdwrt.app/infographics/incretin-atlas/trials/survodutide-phase-2-mash/): Survodutide - [evoke / evoke+](https://docs.mdwrt.app/infographics/incretin-atlas/trials/evoke-evoke/): Semaglutide - [ELAD](https://docs.mdwrt.app/infographics/incretin-atlas/trials/elad/): Liraglutide - [TRIUMPH-1-OSA / TRIUMPH-2-OSA](https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-1-osa-triumph-2-osa/): Retatrutide - [TRIUMPH-4 / TRIUMPH-1-OA](https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-4-triumph-1-oa/): Retatrutide - [ATTAIN-OSA trial 1 / trial 2](https://docs.mdwrt.app/infographics/incretin-atlas/trials/attain-osa-trial-1-trial-2/): Orforglipron - [Phase 2b](https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-2b/): Efinopegdutide - [IMPACT](https://docs.mdwrt.app/infographics/incretin-atlas/trials/impact/): Pemvidutide - [SURMOUNT-MMO](https://docs.mdwrt.app/infographics/incretin-atlas/trials/surmount-mmo/): Tirzepatide - [REDEFINE 3](https://docs.mdwrt.app/infographics/incretin-atlas/trials/redefine-3/): CagriSema - [TRIUMPH-OUTCOMES](https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-outcomes/): Retatrutide - [Orforglipron CVOT](https://docs.mdwrt.app/infographics/incretin-atlas/trials/orforglipron-cvot/): Orforglipron - [MARITIME-CV](https://docs.mdwrt.app/infographics/incretin-atlas/trials/maritime-cv/): MariTide